CFAS Symposium 2021 on "Exercise as Medicine"

June 17th, 2021
Virtual on Zoom (max capacity: 500 attendees)
Registration is closed


On June 17th 2021, the Centre for Physical Activity Research (CFAS) will be hosting a virtual international symposium on “Exercise as Medicine: a translational perspective” - where you will have the opportunity to be updated in the field by excellent lecturers who will present their cutting-edge research. The symposium will include the 2021 Pernille Højman Memorial Lecture and Travel Grant award.
Read more about the travel grant here: The Pernille Højman Travel Grant

Date: June 17th, 2021, 13.00 - 16.50
Venue: Virtual on Zoom (max capacity: 500 attendees)
Price: Free of charge
Program: Symposium program 2021

 

Symposium is at max capacity


Bente Klarlund Pedersen
Professor, Director, Centre for Physical Activity Research (CFAS), Rigshospitalet and University of Copenhagen, Denmark

At CFAS we conduct translational research with the aim of developing exercise as medicine for people with e.g. diabetes, cancer and cardiovascular diseases. The research group has identified skeletal muscle as an endocrine organ that produces and releases signal peptides, which we have named “myokines”.

Ciaran Fairman
Assistant Professor, Exercise Science Department, Arnold School of Public Health, University of South Carolina, USA

Ciaran is an Assistant Professor of Exercise Science and Director of the Exercise Oncology Lab at the University of South Carolina. Ciaran’s primary research focus is examining the impact of exercise, nutrition and supplementation interventions during and after cancer treatments. TSpecific research areas include the manipulation of dose, frequency, volume or intensity of exercise to optimize clinically relevant outcomes in cancer patients; resistance training across the cancer continuum; nutrition/supplementation to augment training adaptations; exercise medicine and tumor biology. Dr. Fairman is also a strong advocate of the dissemination/translation of scientific research to a variety of audiences. He is the host of the REACH podcast, where he discusses the latest research in exercise oncology.

Damien Bailey
Royal Society Wolfson Research Fellow, Professor of Physiology & Biochemistry, Neurovascular Research Laboratory, University of South Wales, UK

 

Damian trained at the Universities of California San Diego (USA), University of Colorado Health Sciences Center (USA) and University of Heidelberg (Germany), before returning to the University of South Wales where he is currently a Royal Society Wolfson Research Fellow and Professor of Physiology & Biochemistry. He is Director of the Neurovascular Research Laboratory that takes an integrated translational approach to examine how free radicals and associated reactive oxygen/nitrogen species regulate substrate delivery to the human brain across the spectrum of health and disease. He also incorporates ‘applied’ models including exercise, spaceflight, skydiving, freediving and high-altitude mountaineering to understand how the human brain adapts to environmental extremes to provide unique, alternative insight into disease pathophysiology.

Daniel Lieberman
Professor and Chair, Department of Human Evolutionary Biology, Harvard University, Cambridge, USA

Daniel Lieberman is Edwin M. Lerner II Professor of Biological Sciences and a professor of the Department of Human Evolutionary Biology at Harvard University. He received degrees from Harvard University and Cambridge University, and taught at Rutgers University and George Washington University before joining Harvard University as a Professor in 2001. He is a member of American Academy of Arts and Sciences. Lieberman studies and teaches how and why the human body is the way it is, and how our evolutionary history affects health and disease. In his research he combines experimental biomechanics, anatomy, and physiology both in the lab and in the field (primarily Kenya and Mexico).  He is best known for his research on the evolution of running and other kinds of physical activities such as walking and throwing, but is also well known for his research on the evolution of the human head. 


Fredrik Karpe

Professor of Metabolic Medicine and Hon. Consultant Physician, University of Oxford, UK

Fredrik Karpe is using genomic and physiological tools to investigate metabolic consequence of obesity and fat distribution. This involves the use of cellular systems (human tissue-specific adipocytes, genetically modified if needed) and human in vivo metabolism using metabolic tracers. Genetic discovery (GWAS using carefully phenotyped individual, for example DXA scan) is performed in identify novel regulatory loci. To promote research in translational medicine he has established the Oxford Biobank consisting of 8,500 deeply phenotyped participants who have given informed

Graham Finlayson
Professor, Chair in Psychobiology, Human Appetite Research Unit, University of Leeds, School of Psychology, Leeds, UK

Graham Finlayson is a psychologist and Professor in Psychobiology in the Faculty of Medicine & Health, University of Leeds, UK. He currently holds a Visiting Professorship at Steno Diabetes Centre Copenhagen. His research focuses on understanding what underpins the control of human appetite and why people overeat. He has published over 150 peer-reviewed research papers with +6,000 total citations.

 

Michael J. Joyner
Professor, The Human and Integrative Physiology and Clinical Pharmacology laboratories, Mayo Clinic, Rochester, USA

Michael J. Joyner, M.D., is the Caywood Professor of Anesthesiology at Mayo Clinic where he was named Distinguished Investigator in 2010. His research focuses on exercise physiology, human performance, blood pressure regulation, metabolism, and transfusion practices.  He is also interested in the limits of scientific reductionism and the de-hyping of biomedical communications.  The latter interest has led to a number of thought provoking and critical essays on the so-called Precision Medicine narrative in the popular press and key scientific journals.  Professor Joyner attended the University of Arizona where he graduated with a B.S. in 1981 and an M.D. in 1987.  After leaving Arizona he completed his residency training in anesthesiology at the Mayo Clinic in 1993 and then developed an independent research laboratory that has been funded by NIH since that time.

Signe Sørensen Torekov
Professor of Clinical Translational Metabolism,, University of Copenhagen, Faculty Of Health and Medical Sciences, Department of Biomedical Sciences, Denmark

Prof Torekov has led seminal studies showing that patients with obesity have low levels of the appetite-inhibiting hormone GLP-1 (Færck and Torekov et al, Diabetes 2015), but that sustained weight loss increases GLP-1 and may thus normalize appetite (Iepsen et al, Torekov, European Journal of Endocrinology 2016). GLP-1 receptor agonist (GLP-1RA) treatment was superior to low-calorie-diet regarding sustained weight loss reduction in blood glucose and increased availability of the appetite-inhibiting hormone leptin (Iepsen et al, Torekov, International Journal of Obesity 2015).

Stefano Balducci
Professor, Department of Clinical and Molecular Medicine, “La Sapienza” University, Rome, Italy

Balducci's research is focused primarily in Physical Activity/Exercise Training interventions in Type 2 diabetes mellitus and its complications. Neuromuscular complication in diabetic patients. Behavioural Intervention Strategy for Adoption and Maintenance of a Physically Active Lifestyle in Type 2 diabetes.